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Glycin-rich antimicrobial peptide 
YD1 from B. amyloliquefaciens, induced 
morphological alteration in and showed affinity 
for plasmid DNA of E. coli
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Abstract 
Antimicrobial peptides (AMPs), low-molecular-weight proteins with broad-spectrum antimicrobial activity, are the 
most promising candidates for the development of novel antimicrobials. A powerful cationic glycine-rich AMP YD1 
(MW ~ 1.0 kDa) was purified from Bacillus amyloliquefaciens CBSYD1 isolated from traditional Korean fermented food 
kimchi, for the treatment of multidrug-resistant (MDR) bacteria. Strain CBSYD1 was identified 99.79% similar to Bacillus 
amyloliquefaciens subsp. plantarum FZB42(T) by 16S rRNA sequence analysis. The amino acid sequence residues of 
YD1 were determined to be Ala-Pro-Lys-Gly-Val-Gln-Gly-Pro-Asn-Gly by Edman degradation method. After the analysis 
and comparison of YD1 peptide sequence using several bioinformatic servers, peptide sequence has been considered 
to be unique. YD1 displayed antimicrobial activity against gram-positive and gram-negative bacteria. The minimal 
inhibitory concentrations (MIC) of YD1 for Escherichia coli KCTC1923 (E. coli), methicillin-resistant Staphylococcus aureus 
B15 (MRSA), and vancomycin-resistant enterococci (VRE) ranged from 8 to 64 µg/mL, representing greater potency than 
commercial reference antibiotics. The antimicrobial mechanism of YD1 was determined to involve cell-penetrating 
translocation inside the cell and interaction with the DNA leading ultimately to bacterial cell death. Analogously, Gly-
Pro-Asn-Gly is the likely expected cell-penetrating motif for YD1. YD1 could be a promising antimicrobial agent for the 
clinical application.
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Introduction
Natural products are extensively used in our society. 
More than 60% of approved drugs and drug candidates 
either are natural goods and/or derived from them. About 
100,000 secondary metabolites (organic compounds, not 
directly involved in the growth, development, or repro-
duction of an organism) with molecular weight less than 
2500  Da have been characterized; half from microbes 
and the other half from plants (Strobel and Daisy 2003). 
AMPs and “bacteriocins” have gained attention for their 
potential application in controlling pathogenic bacteria 
and infectious diseases. AMPs are ubiquitously produced 
by a wide range of microorganisms. Bacillus, a genus 
of significant interest to human health, produces a var-
ied array of AMPs with several different basic chemical 
structures. Several peptides with biological activities have 
been identified from Bacillus and are under active inves-
tigation for their antimicrobial effects (Dischinger et  al. 
2009; Teixeira et al. 2009; Wu et al. 2005). Bacteriocin or 
bacteriocin-like substances have also been described for 
some other important pathogens such as Listeria mono-
cytogenes and Streptococcus pyogenes (Cherif et al. 2001).
The history of use of fermented vegetables as a source 
of beneficial bacteria is extensive. For over 2000  years, 
Koreans have consumed salted and fermented vegetables 
such as kimchi. The primary ingredients of kimchi are 
Baechu cabbage and radish; however, other vegetables 
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such as green onion, leek, and cucumber are also used 
for preparing various types of kimchi. Kimchi contains 
high levels of vitamins, minerals, dietary fibers, and 
other functional ingredients. Many previous studies have 
reported that kimchi has anticancer, antimicrobial, anti-
oxidant, antiatherosclerotic, antidiabetic, and antiobes-
ity effects among others (Islam and Choi 2009; Kim et al. 
2007, 2011).
The rapid development and spread of bacterial resist-
ance and the emergence of multi-drug resistant patho-
gens have created a need for the discovery of new classes 
of antimicrobial agents against novel microbial targets 
while evading existing resistance mechanisms. Elucida-
tion of the mechanism(s) of action of antimicrobial drugs 
helps to characterize the interaction of the pathogen with 
both the chemical and the host, design improved anti-
microbials, determine effective combinations of drugs, 
and understand the development of microbial resistance. 
The exploration of action mechanisms of developmental 
compounds, not originated from target-based discovery, 
should be undertaken early in their development stage 
to facilitate the modification of the drug scaffold for 
improved selectivity of action and pharmaceutical pro-
file. The production of AMPs from bacteria isolated from 
fermented foods and their mechanisms of action have 
not been extensively studied.
In the present work, we designed a two-step study. 
Firstly, we isolated the strain from kimchi, identified, 
characterized, and purified the AMP, and further charac-
terized the AMP designated as YD1. Secondly, upon con-




DEAE-Sepharose Fast Flow and Sephadex G-25 columns 
were obtained from Pharmacia (Uppsala, Sweden). Bac-
terial media de Man-Rogosa-Sharpe (MRS) and Mueller-
Hinton (MH) were purchased from Becton–Dickinson, 
Spark, USA. Agar was purchased from Daejun Chemicals 
and Metals Co, Gyeonggi-do, South Korea. All other rea-
gents were of the extra pure grade. Strain CBSYD1 was 
isolated from fermented kimchi.
Culture media for YD1 production
The impact of various nutrient sources (carbon, nitro-
gen, and metal ion) on the antimicrobial compound 
production was determined and media optimization 
was performed according to our previous report (Cho 
et  al. 2012). Fermentation was carried out in 50  mL 
media in 250-mL Erlenmeyer flasks with constant shak-
ing at 160 rpm. Zone of inhibition was observed against 
Mycobacterium smegmatis ATCC 9341 at every step of 
media optimization. Commercially available MRS and 
MH broth media were used as control media.
Bacterial strain isolation and identification
Cabbages, from different provinces of Korea, were col-
lected and processed for biochemical and molecular 
identification of microorganisms. The strain identifica-
tion, based on morphological characteristics, was made 
according to Bergey’s manual of systematic bacteriology 
(Lechevalier 1989). Furthermore, the identification was 
confirmed by 16S rRNA sequence analysis and phyloge-
netic tree.
The nucleotide sequence of strain CBSYD1 was sub-
mitted to the GenBank (ncbi.nlm.nih.gov/Genbank) 
under the accession no. KY062987.
Antimicrobial activity
A filter paper disc (8 mm, Toyo Roshi Kaisha, Japan) sat-
urated with antimicrobial sample (40 µL) was placed on 
the surface of petri dish (87  mm ×  15  mm) containing 
Mueller Hinton Agar (MHA). The plate was incubated 
at 37  °C, and a clear zone of inhibition surrounding the 
paper disc was measured in millimeter (mm).
An arbitrary unit per milliliter (AU/mL) was defined as 
the reciprocal of the dilution after the last serial dilution 
that resulted in an inhibition zone. The titer of the anti-
microbial substance solution, in AU/mL, was calculated 
as (1000/d) D, where D was the dilution factor, and d was 
the dose, the amount of antimicrobial substance solution 
added to each spot. AU and the zone of inhibition were 
measured against Mycobacterium smegmatis ATCC 9341 
while optimizing CBSYD1 media.
The minimal inhibitory concentration (MIC) was 
determined according to the method described by Wei-
gand et al. (2008).
Purification of YD1
CBSYD1 was cultured for 36  h in optimized media (1% 
peptone, 2% maltose, and 0.01% CaCl2). The cultured 
supernatant was mixed with ammonium sulfate (30–80% 
saturation) and kept at 4 °C with overnight stirring. The 
precipitate was collected by centrifugation at 10,000 rpm 
for 30  min and re-dissolved in 10  mM Tris–HCl buffer 
(pH 7). The dialyzed sample was applied to a DEAE-
Sepharose Fast Flow column (2.5  ×  14  cm) pre-equili-
brated with 10 mM Tris–HCl buffer, pH 7. The column 
was washed with the same buffer and eluted with a lin-
ear gradient of KCl (0–1 M). Fractions of 3 mL were col-
lected at a flow rate of 0.3 mL/min. Active fractions were 
pooled, concentrated, and further purified with Sephadex 
G-25 column (1.5 × 28 cm) using the same buffer system.
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Electrophoresis and in‑situ analysis
The molecular weight of peptide was determined by tri-
cine SDS-PAGE (Schägger 2006). The in situ analysis was 
performed against indicator organism (~5 × 105 cfu/mL) 
by overlaying the processed gel from tricine SDS–PAGE 
[after washes with 50 mM Tris/HCl buffer (pH 7.5) con-
taining 2.5% Triton X-100 for several times] on 0.6% agar 
on Mueller–Hinton (DIFCO, USA) media and incubated 
at 37 °C.
Amino acid sequencing and computational analysis
Amino acid sequence of YD1 was determined by Edman 
degradation using a Procise Model 492 protein sequencer 
(Applied Biosystems, CA, USA). The amino acid 
sequence was analyzed using BLAST search against Gen-
Bank (http://www.ncbi.nlm.nih.gov/BLAST) and Anti-
microbial Peptide Database (http://aps.unmc.edu/AP/
main.php). The 3D structure projection was predicted 
by I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-
TASSER/) under the job ID S281576.
Stability of YD1
The thermal stability of YD1 samples was determined by 
exposure to 20, 40, 60, 80 and 100 °C for 30 min and to 
121 °C/105 kPa for 15 min before analyzing the residual 
activity. Similarly, pH stability was determined over a 
range of pH 2–10 using 1 M NaOH or HCl. The effect of 
protease enzyme on YD1 stability was determined at two 
different enzyme concentrations (1 and 2 mg/mL).
Cytotoxicity
Cytotoxicity assay was performed according to our previ-
ous report by Choi et al. (2016). The murine macrophage 
cell lines Raw 264.7 were seeded in 96-well plates and 
24 h later, treated with purified YD1, concentration rang-
ing 8–120 µg/mL.
Synergism or antagonism of YD1 with antibiotics
YD1 was investigated for the interaction with antibiotics 
such as erythromycin (a protein synthesis translocation 
inhibitor), ceftriaxone sodium (a cell wall synthesis inhib-
itor), and a quinolone (ciprofloxacin) that interferes with 
DNA gyrase supercoiling.
Log phase-grown E. coli and MRSA were cultured 
in MHB at 37  °C and diluted to a final inoculation den-
sity of 1 × 105–1 × 106 cfu/mL in a total of 200 µL. The 
inhibition pattern indicates the interaction between the 
two compounds and the method enables the calculation 
of a fractional inhibitory concentration index (FICI), 
a numerical interpretation of the type of interaction 
displayed.
For wells containing the lowest inhibitory combination 
of drugs, a fractional inhibitory concentration (FIC) is 
derived for each well from the following calculation:
The FIC Index of ≤0.5 was considered to indicate syn-
ergism, a value  ≥4 to indicate antagonism and all val-
ues >0.05 to <4.0 indicated an indifferent interaction (Ji 
1996; Pasquale and Tan 2005; Williams 2001).
Time‑kill interaction between an antibiotic and YD1
Time-kill assays were conducted with concentrations 
corresponding to the MIC values of YD1 and erythromy-
cin for reference strain, E. coli. Concentrations ranging 
from 8 to 256 µg/mL of YD1 or erythromycin were added 
to a bacterial suspension (1 × 105–1 × 106 cfu/mL) of the 
tested bacterial strain. Then, 1 mL of the tested suspen-
sion sample was collected every 1 h for viable cell count-
ing in MHA plate followed by incubation at 37  °C for 
24 h.
Lysis of gram‑negative spheroplasts
Spheroplasts are gram-negative bacteria in which nearly 
all of the outer membrane (OM) has been removed. 
Lysozyme destroys the peptide bonds in peptidoglycan 
and weakens the cell wall. E. coli was grown in 10  mL 
of MHB, incubated overnight at 37  °C on a shaker at 
180  rpm. Each culture (100  µL) was used to inoculate 
20 mL of fresh media and incubated at 37  °C for 2 h at 
180  rpm. Spheroplasts were prepared as described by 
Kikuchi et al. (2015).
Re-suspended spheroplasts and whole cells suspension 
were adjusted to OD 570 nm of 0.2 and 100 µL of each 
was added to a clear, flat-bottomed microtiter plate in 
duplicate wells. Ten microliters of YD1 in 10 mM Tris–
HCl buffer (pH 7) was added to test wells for both prepa-
rations (spheroplasts and whole cells) at the indicated 
different final concentrations. To the control, 10  µL of 
10 mM Tris–HCl buffer (pH 7) was added in lieu of YD1. 
The percentage of intact spheroplasts or whole cells was 
calculated as:
Decrease in the OD of the suspension after addition of 
a membrane-active agent indicates lysis of spheroplasts.
=
MIC of compound A with B
The MIC of compound A alone
+
MIC of compound B with A
The MIC of compound B alone
=
(
Sample OD at time X
Sample OD at time 0
)
× 100
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DNA binding assay
The plasmid DNA (150 ng) of E. coli was incubated with 
increasing concentration of peptides in 20 µL of bind-
ing buffer [5% glycerol, 10 mM Tris–HCl (pH 7), 1 mM 
EDTA, 1  mM DTT, 20  mM KCl, and 50  µg/mL BSA]. 
The reaction mixtures were kept at room temperature 
for 30 min, followed by addition of 4 µL of native loading 
buffer. An aliquot of 12 µL was applied to a 1% agarose 
gel, and electrophoresis was performed in 0.5 X tris–
borate-EDTA buffer.
Transmission electron microscopy (TEM)
TEM analysis was performed according to the method 
described by Lee et al. (2013). Ten milliliters of 106 cfu/
mL E. coli suspension was exposed to 5× MIC (40  µg/
mL) of YD1 to observe morphological changes and calcu-
late the percentage killing of E. coli cells.
Results
Strain isolation and identification
The strain showed a high degree of identity with many 
Bacillus strains in 16S rRNA gene analysis. The closest 
Fig. 1 Neighbor-joining tree based on nearly complete 16S rRNA gene sequences showing relationships between CBSYD1 and some closely 
related taxa of the genus Bacillus. The percentage numbers at the nodes are the levels of bootstrap support based on neighbor-joining analyses of 
1000 resampled data sets
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identity was with Bacillus amyliquefaciens subsp. plan-
tarum FZB42 (99.79%) (Accession no. CP000560). 
Because of a high level of gene similarity, along with iden-
tical morphological characteristics, the strain CBSYD1 
was identified and classified as Bacillus amyliquefa-
ciens CBSYD1. A phylogenetic tree prepared from the 
16S rRNA sequence has been presented in Fig. 1. Strain 
Bacillus amyliquefaciens CBSYD1 has been deposited 
at the Korean collection for type culture (KCTC), which 
is belong to World Data Centre for Microorganisms 
(WDCM), under the accession number KCTC18507P.
Culture media
The effect of various components of nutrition media on 
the production of the antimicrobial compounds in the 
crude sample were emphasized. Among carbon sources, 
2% maltose promoted maximum production and among 
nitrogen sources, it was 1% peptone. Magnesium chlo-
ride or sodium chloride (in 36 h) seemed to be the best 
among minerals. Finally, media containing 1% peptone, 
2% maltose, and 0.01% CaCl2 were determined to be opti-
mum for the maximum antimicrobial production at 37 °C 
after 36  h over commercially available MRS and MH 
broth media (Additional file 1: Figure S1).
Production and antimicrobial activity of YD1
The maximum production of YD1 was achieved in opti-
mized media at 37  °C with shaking at 160 rpm for 36 h 
as shown in Fig. 2. The antibacterial activity (AU/mL) of 
YD1 lasted for 36 h (Fig. 2a) and up to 16 mm of a clear 
zone of inhibition was observed (Fig.  2b). Protein con-
centration increased considerably from 24  h (Fig.  2a) 
onwards. The antibacterial effects of YD1 against various 
gram-positive and gram-negative pathogenic bacteria 
were evaluated. YD1 was effective against Staphylococcus 
aureus, MRSA, and VRE with MIC values of 32, 16, and 
32 µg/mL respectively; E. coli was found to be very sen-
sitive (8  µg/mL) to YD1 whereas reference commercial 
antibiotics exhibited MIC values >128 µg/mL (Table 1).
Purification, molecular weight, and stability of YD1
Production of YD1 was carried out in optimized media. 
The purification of YD1 from the 36 h cultured superna-
tant (ammonium sulfate; 30–80% saturation) of CBSYD1 
is summarized in Table 2. The YD1 was purified to homo-
geneity by a two-step procedure (Fig. 3a, b), resulting in 
40-fold purification and 12% activity recovery. Tricine 
SDS-PAGE analysis showed a single band of YD1 corre-
sponding to a molecular weight of ~1 kDa (Fig. 3c). In the 
bioassay (in situ) step, YD1 presented a zone of inhibition 
corresponding to the same protein band as that observed 
Fig. 2 Production of bacteriocin and the inhibition activity against 
Mycobacterium smegmatis ATCC 9341. Total protein content (black 
square) production increased hourly and antibacterial activity AU/mL 
(down arrow) is maximum at 36 h (a). The zone of inhibition against 
Mycobacterium smegmatis ATCC 9341 at every 12 h is shown (b). 
Cultivation was carried out in 250-mL flasks with 50 mL media, at pH 
7 and 37 °C, with shaking at 160 rpm




 Alcaligenes faecalis ATCC 1004 >128 >128 >128
 Salmonella Typhimurium KCTC 1925 32 64 32
 Escherichia coli KCTC 1923 8 >128 32
 Pseudomonas aeruginosa KCTC 1637 16 >128 >128
Gram-positive bacteria
 Enterococcus faecalis ATCC 29212 64 2 0.5
 Bacillus subtilis ATCC 6633 64 64 2
 Staphylococcus aureus KCTC 1928 32 >128 >128
 Micrococcus luteus ATCC 9341 64 64 1
 Mycobacterium smegmatis ATCC 9341 8 >128 1
 MRSA B15 32 64 >128
 VRE 2 64 32 >128
 VRE 5 64 64 >128
 VRSA >128 >128 >128
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in tricine SDS-PAGE. Stability studies revealed that YD1 
remained completely stable at pH 4–9 and up to 80  °C, 
and its activity decreased sharply at or above 100 °C. The 
protease enzymes failed to alter the antimicrobial activity 
of the YD1 (Additional file 1: Table S1).
Effects of YD1 in Synergism and E. coli cell
Synergism effect was observed for YD1 and erythromycin 
with a mean FICI of 0.48, which suggested that YD1 may 
possess characteristics similar to erythromycin (Table 3; 
Fig. 4). Afterward, TEM was employed to investigate the 
effects of peptide treatment on membrane integrity and 
intracellular changes in E. coli. Typical cell membrane 
and intracellular contents were observed in the untreated 
bacterial cells [Fig. 5a (i), (ii)]. Cells of E. coli exposed to 
5× MIC (40  µg/mL) of YD1 exhibited several changes 
after 4 h incubation. The treated cells showed a decrease 
in size and irregular shape; loss of cytoplasm and light 
staining; plasmolysis; and appearance of bubbles [Fig. 5a 
(iii)]. The microscopic studies have suggested that YD1 
cause no disruption of the cytoplasmic membrane of E. 
coli cell. Further confirmation was established by observ-
ing the lack of lytic action of YD1 in whole cells of E. 
coli and >88% intact surviving spheroplasts [Fig. 5a (iv), 
b]. We hypothesized that the activity of YD1 was asso-
ciated with the inhibition of macromolecular synthesis 
rather than with the damage to the bacterial cell wall. To 
clarify the molecular mechanism of action, the plasmid 
DNA binding affinity of YD1 was measured by analyz-
ing the electrophoretic mobility of the DNA band. As 
shown in Fig. 5c, YD1 suppressed the migration of DNA 
in a dose-dependent manner, at 40  µg/mL concentra-
tion, the DNA migration was suppressed 80% and com-
pletely suppressed the migration of the DNA at 10× MIC 
(>80 µg/mL). Cytotoxicity studies showed that YD1 was 
not toxic to RAW 264.7 macrophage cells. As shown in 
Fig. 5d, YD1 did not exhibit cytotoxicity even at 120 μg/
mL; ~90% of the cells were viable.
Amino acid sequencing and computational analysis
The amino acid sequence residues of YD1 were Ala-
Pro-Lys-Gly-Val-Gln-Gly-Pro-Asn-Gly. The amino acid 
sequence was determined by Edman degradation method 
(Additional file  1: Figure S2) and analyzed using BLAST 
Table 2 Purification steps of YD1
Purification steps Vol (mL) Specific activity (AU/mL) Total activity (AU) Fold Recovery (%)
Cell free supernatant 1000 800 8 × 105 1 100
Ammonium sulphate 52 6400 3.328 × 105 8 41.6
DEAE-Sepharose fast flow 7 25,600 1.792 × 105 32 22.4
Sephadex G-25 3 32,000 0.96 × 105 40 12
Fig. 3 The elution profile of YD1 from a DEAE Sepharose Fast Flow 
ion exchange column (2.5 × 14 cm) (a) and a Sephadex G-25 
permeation column (1.5 x 28 cm) (b). Tricine SDS-PAGE and in situ 
analysis. Lane 1, Sephadex G-25 pooled purified YD1; lane 2, protein 
marker (M); lane 3, 30–80% ammonium sulfate (AS) precipitation frac-
tion; and lane 4, crude sample. Inhibition zone observed in the in situ 
assay is shown in the right panel (c)
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search against GenBank (http://www.ncbi.nlm.nih.gov/
BLAST) and Antimicrobial Peptide Database (http://aps.
unmc.edu/AP/main.php). After undergoing computational 
and sequence analysis using different servers suggested 
that YD1 possesses entirely novel amino acid sequence 
and a coil-shaped secondary structure (Fig. 6a) and has a 
net positive charge of +1 (Table  4). Comparison of YD1 
sequence with other closely related AMP sequences, illus-
trated in Table  4, revealed differences. I-TASSER predic-
tion analysis has suggested the presence of ligand binding 
sites of YD1 in a nucleic acid (NUC) (Fig. 6b).
Discussion
Screening and characterization of novel AMPs are attrac-
tive owing to their potential applications for therapeu-
tic usage and in the food industry. In the present study, 
we identified, purified, and characterized an AMP from 
strains isolated from Korean fermented kimchi. Further-
more, we conducted a preliminary investigation of the 
antimicrobial mechanism of the purified AMP. Till date, 
a few AMPs producing strains have been isolated from 
kimchi (Mah et  al. 2001; Teixeira et  al. 2009; Wu et  al. 
2005). In our present study, we have reported the isola-
tion of AMP producing bacterial strain, CBSYD1, from 
kimchi and studied the influence of several growth media 
and culture conditions on the production of AMP, and 
determined the optimized media (1% peptone, 2% malt-
ose, and 0.01% CaCl2) that promotes greater production 
of YD1 over the commercially available media such as 
MRS and MH (Fig.  2). Growth media temperature and 
nutrients played a major role in the production of bacte-
riocin (Todorov et al. 2006). Bacteriocin activity was sig-
nificantly higher at 37 °C, consistent with the results from 
Lisboa et al. on bacteriocin, produced by B. amyloliquefa-
ciens, (Lisboa et al. 2010) and bacteriocin was very much 
stable at pH 4-9 and up to 80 °C, consistent with results 
by Todorov reports (Todorov et  al. 2006). The protease 
enzymes failed to alter the antimicrobial activity of the 
YD1, which was not unusual (Korenblum et al. 2005). The 
homogeneity of YD1 was obtained by a two-step purifi-
cation procedure, which resulted in 40-fold purification 
with 12% activity recovery. The purified YD1 has lower 
molecular weight compared to a bacteriocin-like sub-
stance (BLS) and some other Bacillus AMPs (Teixeira 
et al. 2009). YD1 was shown to be effective against both 
gram-positive and gram-negative bacteria as presented in 
Table  1. YD1 displayed a better antagonistic effect than 
Table 3 Average FIC indices resulting from chequerboard titrations between YD1 and selected antibiotics
FIC index interpretations: ≤ 0.5, synergism; > 4, antagonism; > 0.5 to < 4.0 indifferent interaction
Antibiotic Ceftriaxone Na Erythromycin Ciprofloxacin HCl
Bacteria Average FICI Interpretation Average FICI Interpretation Average FICI Interpretation
E. coli KCTC 1923 2.19 Indifferent 0.48 Synergism 0.92 Indifferent
MRSA B15 1.15 Indifferent 0.51 Weak synergism/
indifferent
0.99 Indifferent
Fig. 4 Effect of YD1 and erythromycin in combination on the rate of 
kill of E. coli. a Effect of YD1 (µg/mL) alone on E. coli.; b Effect of YD1 
and erythromycin (µg/mL) in equal proportions on E. coli
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Fig. 5 Transmission electron micrographs of E. coli. a (i) and (ii), untreated control of whole (×40 K zoom) and single cell (×100 K zoom) bacterial 
suspension, respectively, showing typical E. coli shapes; a (iii) and (iv), E. coli’s whole (×40 k zoom) and single cell (×100 K zoom) suspension, respec-
tively, treated with 5× MIC (40 µg/mL) of YD1, showing irregular shapes. b Percentage of E. coli spheroplasts and whole cells remaining intact during 
exposure to YD1. Assays were performed in tris buffer with 20% w/v sucrose at OD 570 nm. c Plasmid DNA binding affinity measured for increasing 
amounts of YD1 (concentration ranging from 8–80 µg/mL). d Effects of YD1 on cell viability. Cell viability was measured after 24 h incubation. Sur-
vival rates were tested with MTT assay in Raw 264.7 cells. Raw 264.7 cells were incubated in the presence or absence of 8–120 µg/mL YD1 for 24 h. 
Each bar shows the mean ± S.D of three independent experiments performed in triplicate
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reference antibiotics (bacitracin and vancomycin) against 
MDR pathogens such as MRSA and VRE. Antimicrobial 
effects of YD1 were prominent in comparison to other 
reports of AMPs against MDR, and non-MDR pathogens 
of Bacillus have been published (Dischinger et  al. 2009; 
Sandiford and Upton 2012; Zheng and Slavik 1999).
The amino acid residues of YD1 were Ala-Pro-Lys-
Gly-Val-Gln-Gly-Pro-Asn-Gly. APD search revealed that 
the closest (40%) similarity of YD1 was with an AMP 
Leucrocin I (AP02344) isolated from white blood cell 
extracts of crocodile, Crocodylus siamensis (Pata et  al. 
2011). Furthermore, sequence alignment suggested other 
AMPs (Table  4) showed  ≤40% similarity. Sequences 
comparison with other AMP sequences revealed that 
YD1 possesses unique characteristics. Most of the AMPs 
are minuscule and strongly cationic (Yeung et al. 2011). 
Characteristics of the YD1 protein suggests that it is an 
AMP include: (1) small size (0.924  kDa) with 10 amino 
acids; (2) cationic character (net charge +1); and (3) the-
oretical pI of 8.80 (calculated according to amino acids 
sequences by ProtParam; http://web.expasy.org/prot-
param). Owing to its broad spectrum of antimicrobial 
activity and unique mechanism of action. Initial results 
from our study showed synergism between YD1 and 
erythromycin, a protein synthesis translocation inhibi-
tor, indicating a relationship between their mechanisms 
of action (Odds 2003) and the property of YD1 to inter-
act with intracellular macromolecules rather than the cell 
wall machinery. Using E. coli (106 cfu/mL bacterial sus-
pension) as a model organism, antimicrobial mechanism 
of action study was performed. TEM images showed 
morphological alteration in E. coli when treated with 5x 
MIC (40 µg/mL) of YD1 (Fig. 5a); while >88% of sphero-
plasts remained intact (Fig. 5b), 80% of E. coli cells died 
at the same YD1 concentration (Fig. 5c). This antibacte-
rial action might result from effects on cellular metabo-
lism. Kang et al. (2015) and Li et al. (2014) also reported 
the similar observation of morphological alteration of 
E. coli cells when treated with berberin and α-terpineol 
respectively (Kang et al. 2015; Li et al. 2014). In Fig. 5a, 
we demonstrated that YD1 possesses cell-penetrating 
and translocation ability, likely responsible for its anti-
microbial activity without damaging bacterial cell wall or 
causing without cytotoxicity in RAW 264.7 macrophage 
cells (Fig.  5d). A recent review by Katrin and Neundorf 
(2011) enlisted the commonly used cell-penetrating pep-
tides (CPP) and AMPs (Splith and Neundorf 2011). Fur-
thermore, the positively charged residues in the α-helical 
sequence, and Arg-rich peptide, associate with the lipid 
phosphate groups to neutralize the Arg residue and allow 
the peptide translocation across the membrane (Amand 
et al. 2008; Boman 1995; Su et al. 2009). Recently, a report 
by Xie et  al. (2011) suggested that the position of Pro 
residue in buforin II was more important than the overall 
α-helical content for the translocation (Xie et  al. 2011). 
Consistent with these previous reports, YD1 AMP, a 
positively charged peptide, contains 3 glycines ([G4,7,10]) 
and 2 proline ([P2,8]) residues out of 10 amino acids. The 
antimicrobial potency of YD1 might not be determined 
solely by the coil-shaped secondary structure, but other 
factors such as the type of positive charge or the location 
of Pro might also be vital. In 2012, Jang and his co-work-
ers (Jang et al. 2012) reported two cell-penetrating motifs 
Q-F-P–V-G and Q-W–P-V-G for peptides Buforin IIb 
and Buf IIIa, respectively. Analogously, Q-G-P-N-G is the 
likely expected cell-penetrating motif for YD1. Moreover, 
I-TASSER prediction analysis has suggested the pres-
ence of ligand binding sites in YD1 sequence for a nucleic 
acid (NUC) (Fig. 6b) which was consistent with the DNA 
binding affinity result shown in Fig. 5c.
In spite of the several proposed molecular processes 
regulated by AMPs, it is still unclear which, if any, of 
the hypothesized mechanisms, is responsible for their 
Fig. 6 a Three-dimensional secondary structure projections of YD1. 
b The biological annotations of the target proteins by COACH based 
on the I-TASSER structure prediction. Predicted ligand binding sites 
of YD1. A diagram of hypothetical antimicrobial mechanism for novel 
AMP YD1 (c)
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biological activity (Pálffy et al. 2009). Based on our find-
ings, the antimicrobial mechanism of YD1 may be driven 
by cell-penetration and translocation inside the cell via a 
voltage-gated ion channel possibly (currently in process) 
and followed by interaction with bacterial plasmid DNA 
ultimately leading to bacterial cell death (Fig.  6c). After 
elucidation of complete structural information of the 
YD1 peptide (currently in progress), we will study the in-
depth antimicrobial mechanism of action and synthesize 
AMP analogs.
In summary, the results presented here demonstrate 
the activity of the novel AMP YD1 purified from Bacillus 
amyliquefaciens subsp. plantarum FZB42 isolated from 
Korean fermented kimchi. A broad-spectrum glycine-
rich, low-molecular-weight AMP YD1 exhibits a unique 
antimicrobial mechanism of action characterized by its 
affinity for bacterial DNA, without damaging bacterial 
cell wall. Potent antimicrobial effects of YD1, in particu-
lar against resistant pathogens such as MRSA, VRE, and 
also E. coli, were observed. Our results collectively sug-
gest that YD1 serve as a promising candidate for devel-
oping therapeutic agents for bacterial infections and 
endotoxin shock.
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